Rexmyelocel T

Drug Profile

Rexmyelocel T

Alternative Names: BM-MNCs - Rexgenero; Bone-marrow-derived-mononuclear-cells-Rexgenero; REX-001

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rexgenero
  • Class Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral ischaemia

Most Recent Events

  • 17 Mar 2017 Rexgenero initiates enrolment in a phase III trial for Peripheral ischaemia in Spain (EudraCT2016-003980-21)
  • 07 Jul 2016 Phase-III clinical trials in Peripheral ischaemia in Spain (Intra-arterial) (EudraCT2016-000240-34)
  • 14 Apr 2016 The UK Medicines and Healthcare Products Regulatory Agency (MHRA) grants Promising Innovative Medicine Designation (PIM) for Rexmyelocel-T for the treatment of Peripheralischemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top